ABC | Volume 114, Nº3, Março 2020

Posicionamento Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020 Arq Bras Cardiol. 2020; 114(3):576-596 1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education CommitteeoftheCouncilforHighBloodPressureResearch.Hypertension. 2008;51(6):1403-19. 2. Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension:aretheydifferent?CurrHypertensRep.2014;16(10):485. 3. Modolo R, de Faria AP, Sabbatini AR, Moreno H. Resistant hypertension revisited:definitionandtrueprevalence. JHypertens.2014;32(7):1546. 4. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index,hyperaldosteronism,cardiachypertrophyandvascularstiffness.JHum Hypertens.2011;25(9):532-8. 5. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016;67(6):1085-92. 6. Moreno H, Jr, Coca A. Resistant and refractory hypertension: reflections on pathophysiologyandterminology.BloodPress.2012;21(4):209-10. 7. Yugar-Toledo JC, Brunelli V, Vilela-Martin JF, Fattori A, Moreno H. Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag? Curr HypertensRep.2018;20(3):1-6. 8. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. 9. Scala LC, Magalhães LB , Machado A. Epidemiologia da hipertensão arterial sistêmica. In: Sociedade Brasileira de Cardiologia. Livro texto da SBC. 2a ed. SãoPaulo:Manole;2015.SãoPaulo;2015.p.780-5. 10. Nobre F, Ribeiro AB, Mion D Jr. [Control of arterial pressure in patients undergoing anti-hypertensive treatment in Brazil: Controlar Brazil]. Arq Bras Cardiol.2010;94(5):663-70. 11. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am JHypertens.2015;28(3):355-61. 12. Bangalore S, Davis BR, CushmanWC, Pressel SL, Muntner PM, CalhounDA, etal.Treatment-ResistantHypertensionandOutcomesBasedonRandomized TreatmentGroup inALLHAT.Am JMed.2017;130(4):439-48e9. 13. KriegerEM,DragerLF,GiorgiDMA,PereiraAC,Barreto-FilhoJAS,NogueiraAR, et al. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension OptimalTreatment).Hypertension.2018;71(4):681-90. 14. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidenceandprognosisofresistanthypertension inhypertensivepatients. Circulation.2012;125(13):1635-42. 15. SarafidisPA,BakrisGL.Resistanthypertension:anoverviewofevaluationand treatment. JAmCollCardiol.2008;52(22):1749-57. 16. SimJJ,BhandariSK,ShiJ,LiuIL,CalhounDA,McGlynnEA,etal.Characteristics ofresistanthypertensionina large,ethnicallydiversehypertensionpopulation ofan integratedhealthsystem.MayoClinProc.2013;88(10):1099-107. 17. Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and ClinicalFindings.Hypertension.2017;70(1):5-9. 18. LazaridisAA,SarafidisPA,RuilopeLM.AmbulatoryBloodPressureMonitoring intheDiagnosis,Prognosis,andManagementofResistantHypertension:Stilla MatterofourResistance?CurrHypertensRep.2015;17(10):78. 19. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340-6. 20. MuxfeldtES,CardosoCR,SallesGF.Prognosticvalueofnocturnalbloodpressure reduction inresistanthypertension.Arch InternMed.2009;169(9):874-80. 21. Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P, et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens. 2014;32(12):2332-40;discussion40. 22. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness isan independentpredictorofall-causeandcardiovascularmortality inhypertensivepatients.Hypertension.2001;37(5):1236-41. 23. Chung CM, Cheng HW, Chang JJ, Lin YS, Hsiao JF, Chang ST, et al. Relationship between resistant hypertension and arterial stiffness assessed bybrachial-anklepulsewavevelocity intheolderpatient.Clin IntervAging. 2014 Sep 5;9:1495-502. 24. Brandao AA, Amodeo C, Alcantara C, Barbosa E, Nobre F, Pinto F, et al. I Luso-Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017;108(2):100-8. 25. Salles GF, CardosoCR, Fiszman R,Muxfeldt ES. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistanthypertension.AmHeart J.2010;159(5):833-40. 26. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension.Atherosclerosis.2011;216(1):199-204. 27. da Costa PM, Cortez AF, de Souza F, Mares GS, Dos Santos BDM, Muxfeldt ES. Prognostic impact of baseline urinary albumin excretion rate in patients with resistant hypertension: a prospective cohort study. J HumHypertens. 2018;32(2):139-49. 28. OliverasA,ArmarioP,SierraC,ArroyoJA,Hernandez-del-ReyR,VazquezS,et al.Urinaryalbuminexcretionatfollow-uppredictscardiovascularoutcomesin subjectswithresistanthypertension.Am JHypertens.2013;26(9):1148-54. 29. CortezAF,MuxfeldtES,CardosoCR,SallesGF.PrognosticValueofC-Reactive Protein inResistantHypertension.Am JHypertens.2016;29(8):992-1000. 30. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902. 31. WhiteWB.Ambulatorybloodpressuremonitoringasan investigativetool for characterizingresistanthypertensionanditsrationaltreatment.JClinHypertens (Greenwich).2007;9(1Suppl1):25-30. 32. Williams B, Mancia G, SpieringW, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESHGuidelines for the management of arterial hypertension. Eur Heart J.2018;39(33):3021-104. 33. MalachiasM,PlavnikFL,MachadoCA,MaltaD,ScalaLCN,FuchsS.7thBrazilian Guideline of Arterial Hypertension: Chapter 1 - Concept, Epidemiology and PrimaryPrevention.ArqBrasCardiol.2016;107(3Suppl3):1-6. 34. ManciaG,FagardR.Guidelinesforthemanagementofhypertensionandtarget organdamage:reply. JHypertens.2013;31(12):2464-5. 35. Nobre FMJ, Gomes MAM, Barbosa ECD, Rodrigues CIS, Neves MFT et al. 6ª Diretrizes de Monitorização Ambulatorial da Pressão Arterial e 4ª Diretrizes de Monitorização Residencial da Pressão Arterial. Arq Bras Cardiol 2018; 2018;110(5Supl.1):1-29. 36. Silva GV, MionD. Papel daMAPA e daMRPA na avaliação de pacientes com hipertensãodedifícilcontrole.RevBrasHipertens.2008;15(1):17-20. 37. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory bloodpressuremonitoringpatternofresistanthypertension.BloodPressMonit. 2003;8(5):181-5. 38. Souza WKS, Jardim PCB, Porto LB, Araújo FA, Sousa ALL, Salgado CM. Comparaçãoecorrelaçãoentreautomedida,medidacasualemonitorização ambulatorialdapressãoarterial.ArqBrasCardiol.2011;97(2):148-55. Referências 592